Antimicrobial peptide DP7 with potential activity against SARS coronavirus infections

Zhang, Rui; Jiang, Xiaohua; Qiao, Juan; Wang, Zeng; Tong, Aiping; Yang, Jinliang; Yang, Shengyong; Yang, Li

doi:10.1038/s41392-021-00551-1

Cited by 16 publications

(12 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Detailed thermodynamics analyses, both experimental and computational are needed to clarify this point. Nevertheless, our work and that of others suggests that design of AMP-derived peptides and peptide mimetics could be a useful strategy in combating CoV-2 variants (Bakovic et al, 2021;Diamond et al, 2021;Zhang et al, 2021).…”

Section: Articlementioning

confidence: 76%

HBD-2 binds SARS-CoV-2 RBD and blocks viral entry: Strategy to combat COVID-19

et al. 2022

View full text Add to dashboard Cite

New approaches to complement vaccination are needed to combat the spread of SARS-CoV-2 and stop COVID-19 related deaths and medical complications. Human beta defensin 2 (hBD-2) is a naturally occurring epithelial cell derived host defense peptide that has antiviral properties. Our comprehensive in-silico studies demonstrate that hBD-2 binds the site on the CoV-2-RBD that docks with the ACE2 receptor. Biophysical measurements confirm that hBD-2 indeed binds to the CoV-2-receptor binding domain (RBD) (K D ∼ 2μM by surface plasmon resonance), preventing it from binding to ACE2 expressing cells. Importantly, hBD-2 shows specificity by blocking CoV-2/spike pseudoviral infection, but not VSVG mediated infection, of ACE2 expressing human cells with an IC 50 of 2.8 + 0.4 μM. These promising findings offer opportunities to develop hBD-2 and/or its derivatives and mimetics to safely and effectively use as agents to prevent SARS-CoV-2 infection.

show abstract

Section: Articlementioning

confidence: 76%

HBD-2 binds SARS-CoV-2 RBD and blocks viral entry: Strategy to combat COVID-19

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Several potential SARS-CoV-2 entry inhibitor peptides, and strategies used to design those peptides targeting the ACE2 receptor or the viral spike protein and its activating proteases, have been outlined in a recent review by Schütz et al (2020) . Additionally, peptoid mimics (sequence-specific N -substituted glycine oligomers) of AMPs and an antimicrobial DP7 peptide (VQWRIRVAVIRK) were recently shown to have anti-CoV-2 activity ( Zhang R. et al, 2021 ; Diamond et al, 2021 ). Moreover, a synthetic mimetic of defensins, Brilacidin , has been shown to potently inhibit CoV-2 in an ACE2-positive human lung cell line ( Bakovic et al, 2021 ) and recently received approval by the Federal Drug Administration (FDA) to start a phase 2 clinical trial in COVID-19 patients ( ClinicalTrials.gov ; Identifier: NCT04784897).…”

Section: Discussionmentioning

confidence: 99%

Ramping Up Antimicrobial Peptides Against Severe Acute Respiratory Syndrome Coronavirus-2

Ghosh

Weinberg

2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Human-derived antimicrobial peptides (AMPs), such as defensins and cathelicidin LL-37, are members of the innate immune system and play a crucial role in early pulmonary defense against viruses. These AMPs achieve viral inhibition through a variety of mechanisms including, but not limited to, direct binding to virions, binding to and modulating host cell-surface receptors, blocking viral replication, and aggregation of viral particles and indirectly by functioning as chemokines to enhance or curb adaptive immune responses. Given the fact that we are in a pandemic of unprecedented severity and the urgent need for therapeutic options to combat severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), naturally expressed AMPs and their derivatives have the potential to combat coronavirus disease 2019 (COVID-19) and impede viral infectivity in various ways. Provided the fact that development of effective treatments is an urgent public health priority, AMPs and their derivatives are being explored as potential prophylactic and therapeutic candidates. Additionally, cell-based platforms such as human mesenchymal stem cell (hMSC) therapy are showing success in saving the lives of severely ill patients infected with SARS-CoV-2. This could be partially due to AMPs released from hMSCs that also act as immunological rheostats to modulate the host inflammatory response. This review highlights the utilization of AMPs in strategies that could be implemented as novel therapeutics, either alone or in combination with other platforms, to treat CoV-2–infected individuals.

show abstract

“…Furthermore, using molecular docking and molecular dynamics simulations, Balmeh et al [ 98 ] revealed that glycocin F and lactococcine G were the best bio-AMPs to block RdRp, 3CL, S, and N proteins of SARS-CoV-2, with minimal side effects. It was found that the antibacterial peptide DP7 had a potential effect on inhibiting SARS-CoV-2 infection, through SARS-CoV-2 S protein pseudovirus infection of ACE2-293 T cells, SARS-CoV-2 S protein-mediated cell–cell fusion, and the inhibition of SARS-CoV-2-3CLpro enzyme activity [ 103 ]. These findings reported that AVPs could be effective in treating COVID-19 infection.…”

Section: Potential Use Against Covid-19mentioning

confidence: 99%

Antimicrobial peptides: features, applications and the potential use against covid-19

Mabrouk

2022

Mol Biol Rep

View full text Add to dashboard Cite

Background Antimicrobial peptides (AMPs) are a diverse class of molecules that represent a vital part of innate immunity. AMPs are evolutionarily conserved molecules that exhibit structural and functional diversity. They provide a possible solution to the antibiotic-resistance crisis. Main text These small cationic peptides can target bacteria, fungi, and viruses, as well as cancer cells. Their unique action mechanisms, rare antibiotic-resistant variants, broad-spectrum activity, low toxicity, and high specificity encourage pharmaceutical industries to conduct clinical trials to develop them as therapeutic drugs. The rapid development of computer-assisted strategies accelerated the identification of AMPs. The Antimicrobial Peptide Database (APD) so far contains 3324 AMPs from different sources. In addition to their applications in different fields, some AMPs demonstrated the potential to combat COVID-19, and hinder viral infectivity in diverse ways. Conclusions This review provides a brief history of AMPs and their features, including classification, evolution, sources and mechanisms of action, biosynthesis pathway, and identification techniques. Furthermore, their different applications, challenges to clinical applications, and their potential use against COVID-19 are presented.

show abstract

Antimicrobial peptide DP7 with potential activity against SARS coronavirus infections

Cited by 16 publications

References 5 publications

HBD-2 binds SARS-CoV-2 RBD and blocks viral entry: Strategy to combat COVID-19

HBD-2 binds SARS-CoV-2 RBD and blocks viral entry: Strategy to combat COVID-19

Ramping Up Antimicrobial Peptides Against Severe Acute Respiratory Syndrome Coronavirus-2

Antimicrobial peptides: features, applications and the potential use against covid-19

Contact Info

Product

Resources

About